You are here

A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
JR Sapporo hospital
Sapporo, Hokkaido, 060-0033 Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Are 20 years or older and considered to be candidates for systemic or phototherapy.

[Moderate to Severe Plaque Psoriasis]

- Diagnosed for at least 12 months.

- Have Psoriasis Area and Severity Index (PASI) score of 12 and plaque type psoriasis
covering at least 10% of body surface area (BSA).

[Psoriatic Arthritis]

- Diagnosed for at least 6 months.

- Meet the CASPAR (classification criteria for Psoriatic Arthritis) criteria at
screening;

- Have active arthritis (≥3 tender/painful joints on motion and ≥3 swollen joints), and
active plaque psoriasis with at least 2 cm in diameter.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Non-plaque or drug induced forms of psoriasis

- Cannot discontinue current oral, injectable or topical therapy for psoriasis/psoriatic
arthritis or cannot discontinue phototherapy (PUVA or UVB)

- any uncontrolled significant medical condition

NCT01519089
Pfizer
Completed
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
NCT03885089
All Genders
0+
Years
Tokyo,

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now